Drugs › Low molecular weight heparin
Generic name
Enoxaparin sodium: adverse event reports filed with FDA
10,060 reports list it as a suspect or interacting product, 2004–2026. Class: Low molecular weight heparin. Also reported as Enoxaparin Sodium Injection, Enoxaparin Sodium Injection Usp.
- 10,060
- reports as suspect product
- 0.1% of all reports · about 447 a year
- 761
- reports, 12 months to June 2026
- 1,010 in the 12 months before
- 82.7%
- marked serious by the reporter
- 81.3% across the class
- 18.2%
- record death among outcomes, as reported
- 1,833 reports · not verified by FDA
10,060 adverse event reports received by FDA list enoxaparin sodium, a generic name as a suspect or interacting product, from January 2004 to June 2026. A further 11,446 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 761 reports listed it, down 25% from 1,010 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 447 reports a year and 0.1% of the 20,646,523 reports in the database, and 39.9% of the reports for the low molecular weight heparin class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded dyspnoea (4.5%), off label use (4.3%) and exposure during pregnancy (4.3%). A report can list several reactions, so shares add to more than 100%; 1,324 different terms appear across these reports. Dyspnoea is recorded in 4.5% of these reports, a larger share than in the median low molecular weight heparin drug (3.1%).
82.7% of the reports are marked serious by the reporter (81.3% across the class); 18.2% record death among the outcomes and 40.4% record hospitalisation, as reported. 38.7% of the reports came from other health professionals, and the largest patient age group is 75 and over (18.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Enoxaparin sodium reports recording the termmedian drug in low molecular weight heparin
- Dyspnoeashortness of breath4.5%454
- Off label useused for a purpose or in a way not on the label4.3%432
- Exposure during pregnancythe medicine was taken during pregnancy4.3%428
- Nauseafeeling sick3.9%392
- Maternal exposure during pregnancythe mother took the medicine during pregnancy3.8%382
- Foetal exposure during pregnancythe unborn baby was exposed to the medicine3.8%379
- Abdominal painstomach or belly pain3.6%359
- Anaemialow red blood cells3.6%359
- Drug ineffectivethe medicine did not work as expected3.6%359
- Pruritusitching3.5%355
- Thrombocytopenialow platelets3.4%346
- Vomitingbeing sick3.4%346
- Device malfunctionthe device did not work properly3.4%344
- Headachehead pain3.4%344
- Tachycardiafast heart rate3.3%334
- Sepsisa severe body-wide response to infection3.3%330
- Pyrexiafever3.3%327
- Haemorrhagebleeding3.2%325
- Haemoglobin decreasedlow haemoglobin3.2%322
- Drug interactionan interaction between medicines3.2%321
- Dizzinesslight-headedness or unsteadiness3.1%316
- Pulmonary embolisma blood clot in the lung3.1%315
- Haematuriablood in the urine3.1%313
- Diarrhoealoose or frequent stools3.1%310
- Haematomaa collection of blood under the skin or in tissue3.1%308
- No adverse eventno adverse event was reported3%304
- Condition aggravatedthe condition being treated got worse3%301
- Haematemesis3%300
- Falla fall3%298
- Astheniaweakness or lack of energy2.9%294
Top 30 of 1,324 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 2 drugs in the low molecular weight heparin class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 25,243 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 32.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Thrombosis prophylaxis | 1,180 | 11.7% |
| Anticoagulant therapy | 604 | 6% |
| Deep vein thrombosis | 453 | 4.5% |
| Pulmonary embolism | 401 | 4% |
| Prophylaxis | 370 | 3.7% |
| Atrial fibrillation | 260 | 2.6% |
The indication field is filled in by the reporter and is often blank; shares are of all 10,060 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Enoxaparin sodium reports |
|---|---|---|
| Aspirin | 1,697 | 16.9% |
| Acetaminophen | 1,049 | 10.4% |
| Furosemide | 566 | 5.6% |
| Simvastatin | 523 | 5.2% |
| Warfarin sodium | 458 | 4.6% |
| Esomeprazole | 404 | 4% |
| Dexamethasone | 388 | 3.9% |
| Bisoprolol | 379 | 3.8% |
| Bisoprolol fumarate | 374 | 3.7% |
| Hydrochlorothiazide | 372 | 3.7% |
Other products listed in reports where Enoxaparin sodium is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Enoxaparin sodium | Low molecular weight heparin | All reports |
|---|---|---|---|
| Reports as suspect product | 10,060 | 25,243 | 20,646,523 |
| Share of that pool | — | 39.9% | 0.1% |
| Reports, latest 12 months | 761 | — | 1,332,454 |
| Marked serious | 82.7% | 81.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 182 | 157 | 91 |
| Hospitalisation recorded, per 1,000 reports | 404 | 443 | 213 |
| Consumer-filed share | 18.3% | 24.2% | 45.8% |
| Top term, share of reports | Dyspnoea 4.5% | median 3.1% | 2.7% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the low molecular weight heparin class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Lovenox | brand | 15,183 | 774 | 80.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Enoxaparin sodium reports
How many adverse event reports has FDA received for Enoxaparin sodium?
10,060 reports list Enoxaparin sodium as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 761 of them arrived in the latest 12 months. Another 11,446 list it only as a concomitant medication.
What reactions are recorded in Enoxaparin sodium reports?
dyspnoea (4.5%), off label use (4.3%), exposure during pregnancy (4.3%), nausea (3.9%) and maternal exposure during pregnancy (3.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Enoxaparin sodium was responsible.
How serious are the reports?
82.7% are marked serious by the reporter. Among the outcomes recorded, 18.2% of reports include death and 40.4% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (38.7%), physician (24.8%) and consumer or non-health professional (18.3%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Enoxaparin sodium rising?
761 reports in the 12 months to June 2026, down 25% from 1,010 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Enoxaparin sodium was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Enoxaparin sodium?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Enoxaparin sodium as a suspect or interacting product; reports listing it only as a concomitant medication (11,446) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.